Aug. 27 – 28, 2015
Masur Auditorium, Building 10
Diabetic retinopathy remains the leading cause of vision loss in middle-aged adults. Blindness is increasing rapidly worldwide due to this devastating disease. By bringing together basic and clinician scientists, students and established investigators, this conference focused on an integrated approach to fight this epidemic – both current challenges and what remains to be done.
Over 382 million people in the world have diabetes, and it is estimated that this number will reach around 600 million by 2035. Early detection and prompt treatment are still the gold standards of managing diabetic retinopathy, and landmark clinical trials have shown that such treatment can effectively decrease visual disability by 90%. Despite tremendous progress in the developments of treatment for this devastating disease, many questions remain unanswered.
This two-day conference served as a continuation of the 2010 ARVO Diabetic Retinopathy conference by featuring newly released research and recent advances in oral and poster presentations, as well as panel discussions made by academia, industry and clinical participants.
The educational design of this activity addressed the needs of basic and clinician scientists involved in the research and/or treatment of patients with diabetic retinopathy.
- Summarize current concepts about molecular mechanisms, laser and surgical treatments of diabetic retinopathy.
- Describe new concepts on the horizon
- Discuss current clinical trials of new pharmacotherapies of diabetic retinopathy
- Analyze the challenges ahead for future clinical trials
- Identify new targets and formulate research strategies to develop new therapies and clinical trials.
- Lloyd P. Aiello, MD, PhD, Joslin Diabetes Center
- Arup Das, MD, PhD, University of New Mexico School of Medicine
- Maria Grant, MD, Indiana University
- Renu Kowluru, PhD, Wayne State University
Contact ARVO Education at DRConference@arvo.org